Vimarsana
Biggest News Aggregation in the World

Becker Hewes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Becker Hewes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Becker Hewes Today - Breaking & Trending Today

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting - Vimarsana News

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with...

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting - Vimarsana News

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis - Vimarsana News

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2023 Earnings Call Transcript - Vimarsana News

Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2023 Earnings Call Transcript

Operator: Good morning, ladies and gentlemen. My name is Glen. I'll be your conference operator today.

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting - Vimarsana News

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at...